Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium.
نویسندگان
چکیده
Prostaglandin I2 (prostacyclin, PGI2), a substance synthesized in the wall of blood vessels, has been previously shown to inhibit the aggregation of platelets in stirred platelet-rich plasma. We used a method in which segments of deendothelialized rabbit aorta are perfused at arterial shear rates with human blood and found that both platelet adhesion and thrombus formation on subendothelium was inhibited in blood containing 10 nM PGI2. PGI2 appears to reduce adhesion by inhibiting platelet spreading. These findings suggest that PGI2 could regulate the deposition of platelets on vascular surfaces.
منابع مشابه
Prostacyclin ( Prostaglandin 12 , PGI 2 ) Inhibits Platelet Adhesion and Thrombus Formation on Subendothelium
Prostaglandin I2 (prostacyclin, PGI2), a subadhesion and thrombus formation on subenstance synthesized in the wall of blood dothelium was inhibited in blood containing vessels, has been previously shown to inhibit 10 nM PGI2. PGI2 appears to reduce adhesion the aggregation of platelets in Stirred plateby inhibiting platelet spreading. These findlet-rich plasma. We used a method in which ings su...
متن کاملProstacyclin ( Prostaglandin 12 , PGI 2 ) Inhibits Platelet Adhesion and Thrombus Formation on
Prostaglandin I2 (prostacyclin, PGI2), a subadhesion and thrombus formation on subenstance synthesized in the wall of blood dothelium was inhibited in blood containing vessels, has been previously shown to inhibit 10 nM PGI2. PGI2 appears to reduce adhesion the aggregation of platelets in Stirred plateby inhibiting platelet spreading. These findlet-rich plasma. We used a method in which ings su...
متن کاملEffects of prostacyclin on tumor cell-induced platelet aggregation.
Prostacyclin has been evaluated for its ability to inhibit tumor cell-induced platelet aggregation (TCIPA) induced by several rodent tumor lines: B16a (melanoma); 3LL (carcinoma); 15091A (adenocarcinoma); and W256 (carcinosarcoma). Aggregation of human platelets by all four lines was inhibited by prostaglandin I2 (PGI2) in a dose-dependent manner, with complete inhibition observed at 10 ng/ml. ...
متن کاملSynergistic inhibition of platelet activation by plasmin and prostaglandin I2.
Endothelial cell prostacyclin (PGI2) inhibits platelet activation by raising platelet cyclic AMP. Previously, platelet activation was also shown to be blocked by plasmin formed by endothelium-derived tissue plasminogen activator (TPA). We have now studied interactions between PGI2 and plasmin in the control of platelet function. PGI2 and plasmin cause synergistic inhibition of thrombin- and ADP...
متن کاملTransdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.
BACKGROUND Even low doses of oral aspirin inhibit prostacyclin (prostaglandin [PG] I2) formation and cause gastrointestinal toxicity. We examined the skin as a novel route for continuous low-dose aspirin administration and selective inhibition of platelet cyclooxygenase in humans. METHODS AND RESULTS Aspirin 250 or 750 mg/d for 10 days induced a dose-dependent inhibition of serum thromboxane ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 53 2 شماره
صفحات -
تاریخ انتشار 1979